Toll-like receptors as potential therapeutic targets for multiple diseases

Nature Reviews Drug Discovery

Volumn 1, Issue 10, 2002, Pages 797-807

  Zuany Amorim, Claudia ^a   Hastewell, John ^a   Walker, Christoph ^a  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BACTERIAL VACCINE; BCG VACCINE; CD14 ANTIGEN; CORTICOSTEROID; CYCLOOXYGENASE 2; DNA; DNA VACCINE; FATTY ACID; IMIQUIMOD; LIGAND; OLIGONUCLEOTIDE; QUINOLONE DERIVATIVE; RECEPTOR ACTIVITY MODIFYING PROTEIN; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; CELL SURFACE RECEPTOR; DROSOPHILA PROTEIN; MEMBRANE PROTEIN;

ALLERGY; ASTHMA; ATOPY; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CHRONIC INFLAMMATION; CPG ISLAND; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; GENITAL HERPES; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SKIN DISEASE; TH1 CELL; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; IMMUNOLOGY; INFLAMMATION; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; DROSOPHILA PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS;

EID: 0036780681     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd914     Document Type: Review

References (119)

1. Janeway, C. A. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
2. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M. & Hoffman, J. A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifugal response in Drosophila adults. Cell 86, 973-983 (1996).
3. Poltorak, A. et al. Defective LPS signalling in C3H/Hej and C57BL/10ScCr mice: mutations in TLR-4 gene. Science 282, 2085-2088 (1998).
4. Medzhitov, R. Toll-like receptors and innate immunity. Nature Immunol. 1, 135-145 (2001).
5. Imler, J. L. & Hoffmann, J. A. Toll-like receptors in innate immunity. Trends Cell Biol. 11, 304-311 (2001).
6. Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2, 675-680 (2001).
7. Hoshino, K. et al. Cutting edge: Toll-like receptor-4 (TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR-4 as the LPS gene product. J. Immunol. 162, 3749-3752 (1999).
8. Underhill, D. M. & Ozinsky, A. Toll-like receptors: key mediators of microbe detection, Curr. Opin. Immunol. 14, 103-110 (2002).
9. Wertz, C. et al. Leptospiral lipopolysaccharide activates cells through a TLR-2-dependent mechanism. Nature Immunol. 2, 346-352 (2001).
10. Hirschfeld, M. et al. Signalling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 69, 1477-1482 (2001).
11. Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103 (2001).
12. Hemmi, H. et al. A Toll-like receptor recognises bacterial DNA. Nature 408, 740-745 (2000).
13. Alexopoulou, L., Czopik-Holt, A., Medzhitov, R. & Flavell, R. Recognition of double stranded RNA and activation of NFκB by Toll-like receptor 3. Nature 413, 696-712 (2001).
14. Takeuchi, O. et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169, 10-14 (2002).
15. Medzhitov, R. et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signalling pathways. Mol. Cell 2, 253-258 (1998).
16. Cao, Z., Henzel, W. J. & Gao, X. IRAK: a kinase associated with the interleukin-1 receptor. Science 271, 1128-1131 (1996).
17. Cao, Z., Xiong, J., Takeuchi, M., Kurama, T. & Goeddel, D. V. TRAF6 is a signal transducer for interleukin-1. Nature 383, 443-446 (1996).
18. Bulut, Y., Faure, E., Thomas, L., Equils, O. & Arditi, M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J. Immunol. 167, 987-994 (2001).
19. Fitzgerald, K. A. et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413, 78-83 (2001).
20. Kawai, T., Adachi, O., Ogawa, T., Takeda, K. & Akira, S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115-122 (1999).
21. O'Neill, L. A. J. Toll-like receptor signal transduction and the tailoring of innate immunity: a role for Mal. Trends Immunol. 23, 296-300 (2002).
22. Kaisho, T., Takeuchi, O., Kawai, T., Hoshino, K. & Akira, S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J. Immunol. 166, 5688-5694 (2001).
23. Gutierrez-Ramos, J. C. & Bluethmann, H. Molecules and mechanisms operating in septic shock: lessons from knockout mice. Immunol. Today 18, 329-334 (1997).
24. Warren, H. S. Strategies for the treatment of sepsis. New Engl. J. Med. 336, 952-953 (1997).
25. Knuefermann, P. et al. Cardiac inflammation and innate immunity in septic shock. Is there a role for Toll-like receptors? Chest 121, 1329-1336 (2002).
26. Opal, S. M. & Huber, C. E. Bench-to-bedside review: Toll-like receptors and their role in septic shock. Crit. Care 6, 125-136 (2002).
27. H2-like cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol. Sci. 15, 324-332 (1994).
28. H2-like bronchoalveolar lavage T-lymphocyte population in atopic asthma. New Engl. J. Med. 326, 298-304 (1992).
29. Corry, D. B. & Kheradmand, F. Induction and regulation of the IgE response. Nature 402, B18-B23 (1999).
30. Bacharier, L. B. & Geha, R. S. Molecular mechanisms of IgE regulation. J. Allergy Clin. Immunol. 105, S547-S558 (2000).
31. Sanderson, C. J. IL-5, eosinophils and disease. Blood 79, 3101-3109 (1992).
32. Bousquet, J., Jeffery, P. K., Busse, W. W., Johnson, M. & Vignola, A. M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 161, 1720-1745 (2000).
33. Lemanske, R. F. & Busse, W. W. Asthma. JAMA 278, 1855-1873 (1997).
34. Wills-Karp, M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255-281 (1999).
35. Holt, P. G. et al. The role of allergy in the development of asthma. Nature 402, B12-B17 (1999).
36. Holt, P. G. et al. Genetic risk for atopy is associated with delayed postnatal maturation of T cell competence. Clin. Exp. Allergy 22, 1093-1099 (1992).
37. Martinez, F. D. & Holt, P. G. Role of microbial burden in aetiology of allergy and asthma. Lancet 354 (Paediatrics Suppl. 2), 12-15 (1999).
38. Matricardi, P. M. et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiologic study. BMJ 320, 412-417 (2000).
39. Illi, S. et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ 322, 390-395 (2001).
40. Shirakawa, T., Enomoto, T., Shimazu, S. & Hopkin, J. M. The inverse association between tuberculin responses and atopic disorder. Science 276, 77-79 (1997).
41. von Mutius, E. et al. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. Eur. Respir. J. 14, 4-11 (1999).
42. Wickens, K., Pearce, N., Crane, J. & Beasley, R. Antibiotic use in early childhood and the development of asthma. Clin. Exp. Allergy 29, 766-771 (1999).
43. Erb, K. J., Holloway, J. W., Sobeck, A., Moll, H. & Le Gros, G. Infection of mice with Mycobacterium bovis Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J. Exp. Med. 187, 561-569 (1998).
44. H1 murine helper T lymphocyte clones. J. Immunol. 140, 4245-4252 (1988).
45. Schnare, M. et al. Toll-like receptors control activation of adaptive immune responses. Nature Immunol. 2, 947-950 (2001).
46. Johnston, S. L. Mechanisms of asthma exacerbation. Clin. Exp. Allergy 28, 181-186 (1998).
47. Message, S. D. & Johnston, S. L. Viruses in asthma. Br. Med. Bull. 61, 29-43 (2002).
48. Kurt-Jones, E. A. et al. Pattern recognition receptors TLR-4 and CD14 mediate response to respiratory syncytial virus. Nature Immunol. 1, 398-401 (2000).
49. Holla, A. D., Roy, S. R. & Liu, A. H. Endotoxin, atopy and asthma. Curr. Opin. Allergy Clin. Immunol. 2, 141-145 (2002).
50. Papadopoulos, N. G., Stanciu, L. A., Papi, A., Holgate, S. T. & Johnston, S. L. A defective type 1 response to rhinovirus in atopic asthma. Thorax 57, 328-332 (2002).
51. Pulendran, B. et al. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. 167, 5067-5076 (2001).
52. + T lymphocytes aquired in response to Mycobacterium tuberculosis infection. J. Immunol. 151, 518-525 (1993).
53. von Hertzen, L. C. & Haahtela, T. Could the risk of asthma and atopy be reduced by a vaccine that induces a strong T-helper type 1 response? Am. J. Respir. Cell Mol. Biol. 22, 139-142 (2000).
54. Shirakawa, T. et al. The inverse association between tuberculin responses and atopic disorder. Science 275, 77-79 (1997).
55. Erb, K. J. et al. Infection of mice with Mycobacterium bovis Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia J. Exp. Med. 187, 561-569 (1998).
56. Herz, U. et al. BCG infection suppresses allergic sensitisation and development of increased airway reactivity in an animal model. J. Allergy Clin. Immunol. 102, 867-874 (1998).
57. Wohlleben, G. & Erb, K. L. Atopic disorders: a vaccine around the corner? Trends Immunol. 22, 618-625 (2001).
58. Wang, C. C. & Rook, G. A. Inhibition of an established allergic response to ovalbumin in Balb/c mice by killed Mycobacterium vaccae. Immunology 93, 307-313 (1998).
59. Hopkins, J. M. in New Drugs For Asthma, Allergy and COPD (eds Hansel, T. T. & Barnes, P. J.) 226-228 (Karger, Basel, Switzerland, 2001).
60. Arkwright, P. D. & David, T. J. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J. Allergy Clin. Immunol. 107, 531-534 (2001).
61. Shirtcliffe, P. M. et al. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am. J. Respir. Crit. Care Med. 163, 1410-1414 (2001).
62. Park, J. H., Gold, D. R., Spiegelman, D. L., Burge, H. A. & Milton, D. K. House dust endotoxin and wheeze in the first year of life. Am. J. Respir. Crit. Care Med. 163, 322-328 (2001).
63. Gereda, J. E. et al. Relation between house dust endotoxin exposure, type 1 T cell development and allergen sensitiation in infants at high risk of asthma. Lancet 355, 1680-1683 (2000).
64. Vercelli, D. et al. CD14: a bridge between innate immunity and adaptive IgE responses. J. Endotoxin Res. 7, 45-48 (2001).
65. Koppelman, G. H. et al. Association of a promoter polymorphism of the CD14 gene and atopy. Am. J. Respir. Crit. Care Med. 163, 965-969 (2001).
66. Persing, D. H. et al. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds. US Patent Application WO 01/90129 A2/(2002).
67. Slater, J. E. et al. Lipopolysaccharide augments IgG and IgE responses of mice to the latex allergen Hev b5. J. Allergy Clin. Immunol. 102, 977-983 (1998).
68. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR-7 MyD88-dependent signaling pathway. Nature Immunol. 3, 196-200 (2002).
69. Jurk, M. et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nature Immunol. 3, 499 (2002).
70. Berman, B. Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology. Int. J. Dermatol. 29, 7-11 (2002).
71. Tokunaga, T. et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterisation and antitumor activity. J. Natl Cancer Inst. 72, 955-962 (1998).
72. Davis, H. L. Use of CpG DNA for enhancing specific immune responses. Curr. Top. Microbiol. Immunol. 247, 171-183 (2000).
73. Klinman, D. M. et al. CpG motifs present in bacteria DNA rapidly induce lymphocyte to secrete IL-6, IL-12, and IFN-γ. Proc. Natl Acad. Sci. USA 93, 2879-2883 (1996).
74. Krieg, A. M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta 1489, 107-116 (1999).
75. Tighe, H. et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106, 124-134 (2000).
76. Lewis, A. P. & Ray, K. P. Toll-like receptor. US Patent application WO 01/55386 A1 (2001).
77. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
78. Wohlleben, G. & Erb, K. J. Atopic disorders: a vaccine around the corner? Trends Immunol. 22, 618-625 (2001).
79. + T cells and costimulatory pathways of T-cell activation in protection of non-obese diabetic (NOD) mice from diabetes. Immunology 96, 600-605 (1999).
80. Roncarolo, M. G. & Levings, M. K. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr. Opin. Immunol. 12, 676-683 (2000).
81. Maloy, K. J. & Powrie, F. Regulatory T cells in the control of immune pathology. Nature Immunol. 2, 816-822 (2001).
82. Zuany-Amorim, C. et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T cells. Nature Med. 8, 625-629 (2002).
83. Janeway, C. A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quantit. Biol. 54, 1-13 (1989).
84. Janeway, C. A. Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11-16 (1992).
85. Wedzicha, J. A. Exacerbations: etiology and pathophysiologic mechanisms. Chest 121, 136S-141S (2002).
86. Hausmann, M. et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122, 1987-2000 (2002).
87. Kim, J. et al. Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol. 169, 1535-1541 (2002).
88. Hugot, J. P. et al. Association of NOD2 leurine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
89. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
90. H1 responses. J. Clin. Invest. 98, 1010-1020 (1996).
91. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
92. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301-305 (2002).
93. Ohashi, K. et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like-receptor-4 complex. J. Immunol. 164, 558-561 (2000).
94. Vabulas, R. M. et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem. 277, 15107-15112 (2002).
95. Asea, A. et al. Novel signal transduction pathway utilised by extracellular HSP70: role of Toll-like receptor (TLR)2 and TLR4. J. Biol. Chem. 277, 15028-15034 (2002).
96. Lee, J. Y. et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276, 16683-16689 (2001).
97. Termeer, C. et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor-4. J. Exp. Med. 195, 99-111 (2002).
98. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B-cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002).
99. Guillot, L. et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J. Immunol. 168, 5989-5992 (2002).
100. Singh-Jasuja, H. et al. The role of heat shock proteins and their receptors in the activation of the immune system. Biol. Chem. 382, 629-636 (2001).
101. Mollenhauer, J. & Schulmeister, A. The humoral immune response to heat shock proteins. Experientia 48, 644-649 (1992).
102. Schultz, D. R. & Arnold, P. I. Heat shock (stress) proteins and autoimmunity in rheumatic diseases. Semin. Arthritis Rheum. 22, 357-374 (1993).
103. Dybdahl, B. et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through Toll-like receptor-4. Circulation 105, 685-690 (2002).
104. Kirklin, J. K. et al. Cardiopulmonary bypass: studies on its damaging effects. Blood Purif. 5, 168-178 (1987).
105. Cremer, J. et al. Systemic inflammatory response syndrome after cardiac operations. Ann. Thorac. Surg. 61, 1714-1720 (1996).
106. Demidov, O. N. et al. Heat shock proteins in cardiosurgery patients. Eur. J. Cardiothorac. Surg. 16, 444-449 (1999).
107. Wallin, R. P. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23, 130-135 (2002).
108. Hwang, D. Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through Toll-like receptor 4-derived signaling pathways. FASEB J. 15, 2556-2564 (2001).
109. Raetz, C. R. Biochemistry of endotoxins. Annu. Rev. Biochem. 59, 129-170 (1990).
110. Netea, M. G. et al. Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? Trends Immunol. 23, 135-139 (2002).
111. Agren, U. M. et al. Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture. Free Radic. Biol. Med. 23, 996-1001 (1997).
112. Weigel, P. H. et al. A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J. Theor. Biol. 119, 219-234 (1986).
113. Laurent, T. C. & Fraser, J. R. Hyaluronan. FASEB J. 6, 2397-2404 (1992).
114. Noble, P. W. et al. Hyaluronan fragments activate an NF-κB/l-κB auto-regulatory loop in murine macrophages. J. Exp. Med. 183, 2373-2378 (1996).
115. Termeer, C. J. et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J. Immunol. 165, 1863-1870 (2000).
116. Tan, E. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 44, 93-151 (1989).
117. Rifkin, I. R. et al. Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J. Immunol. 165, 1626-1633 (2000).
118. Shlomchik, M. J. et al. The role of clonal selection and somatic mutation in autoimmunity. Nature 328, 805-811 (1987).
119. The Canadian Hydroxychloroqine Study Group. A randomised study on the effect of withdrawing hydroxychloroquine in systemic lupus erythematosus. N. Engl. J. Med. 324, 150-154 (1991).